NNVC

NanoViricides Inc

Feb 19 • 04:00PM ET

1.01

-0.03 -2.88 %

Healthcare • Biotechnology • USA • AMEX

Today, 3:45 PMNanoViricides reported its fiscal quarter ended December 31, 2025 and announced that its broad‑spectrum antiviral NV-387 has received conditional ACOREP approval to advance into a Phase II MPox trial in the DRC, alongside filings for FDA Orphan Drug Designation in Measles, MPox and Smallpox.

Peers: PFE MRNA BNTX GILD NVAX ADMA VXRT ALT GOVX AIM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.48	Insider Own	2.78%	Shs Outstand	21.60M	Perf Week	0.00%
Market Cap	21.81M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	0.00%	Shs Float	20.99M	Perf Month	-10.62%
Enterprise Value	16.66M	PEG	-	EPS next Q	-0.08	Inst Own	14.38%	Short Float	3.76%	Perf Quarter	-30.82%
Income	-8.32M	P/S	-	EPS this Y	44.44%	Inst Trans	0.73%	Short Ratio	2.52	Perf Half Y	-29.86%
Sales	0.00M	P/B	1.97	EPS next Y	0.00%	ROA	-69.79%	Short Interest	0.79M	Perf YTD	-10.62%
Book/sh	0.51	P/C	4.24	EPS next 5Y	17.79%	ROE	-77.53%	52W High	2.23 -54.71%	Perf Year	-26.28%
Cash/sh	0.24	P/FCF	-	EPS past 3/5Y	3.77% 23.52%	ROIC	-75.13%	52W Low	0.85 18.82%	Perf 3Y	-30.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.17% 7.38%	Perf 5Y	-79.60%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	32.91%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-97.13%
Dividend Ex-Date	-	Quick Ratio	4.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.06	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.43	EPS Q/Q	19.55%	SMA20	0.78%	Beta	1.30	Target Price	6.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-10.72%	Rel Volume	0.47	Prev Close	1.04
Employees	7	LT Debt/Eq	0.00	Earnings	Dec 03	SMA200	-27.17%	Avg Volume	312.95K	Price	1.01
IPO	Aug 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	50.00% -	Trades		Volume	148,078	Change	-2.88%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-25	Initiated	Alliance Global Partners	Buy
Feb-11-15	Initiated	Midtown Partners	Strong Buy	$5.30

Today 03:30PM	Dow Jones leads Wall Street lower, US-Iran fears drive oil higher (Proactive)
08:27AM	NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study (Proactive)
Feb-17-26 04:54PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-12-26 03:50PM	Dow drops below 50,000 as S&P 500 falls back under years opening level (Proactive) -7.92%
09:23AM	NanoViricides seeks FDA orphan status for MPox drug (Proactive)
08:30AM	Loading…
08:30AM	MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides (ACCESSWIRE)
Feb-10-26 09:13AM	NanoViricides seeks orphan drug status with US FDA for measles treatment (Proactive) +8.02%
08:30AM	Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides (ACCESSWIRE)
Feb-02-26 08:30AM	NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres (ACCESSWIRE)
Jan-13-26 08:30AM	NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 (ACCESSWIRE) +6.19%
Dec-12-25 09:51AM	2 Small-Cap Biotechs That Could Reward Patient Investors (MarketBeat)
Dec-01-25 08:30AM	NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles (ACCESSWIRE) -8.20%
Nov-17-25 08:30AM	NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position (ACCESSWIRE)
Nov-14-25 05:41PM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +5.19%
08:30AM	NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 (ACCESSWIRE)
05:01PM	Loading…
Nov-12-25 05:01PM	NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (ACCESSWIRE) -5.66% -10.00%
Nov-11-25 08:30AM	NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (ACCESSWIRE) -5.36%
Nov-10-25 08:30AM	NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (ACCESSWIRE) -8.70%
Nov-05-25 08:30AM	NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT (ACCESSWIRE)
Nov-03-25 08:30AM	NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd (ACCESSWIRE) +22.29%
Oct-29-25 08:45AM	Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive (ACCESSWIRE) +21.57%
Oct-27-25 08:45AM	NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 (ACCESSWIRE) +5.23%
Oct-22-25 08:45AM	In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides (ACCESSWIRE)
Oct-20-25 08:45AM	A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus (ACCESSWIRE)
Oct-15-25 08:45AM	NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses (ACCESSWIRE) +6.67%
Sep-30-25 08:45AM	NanoViricides, Inc. Has Filed its Annual Report (ACCESSWIRE)
Sep-11-25 08:30AM	RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 (ACCESSWIRE)
Sep-09-25 08:30AM	NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 (ACCESSWIRE)
Aug-18-25 08:30AM	A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials (ACCESSWIRE)
Jul-30-25 08:30AM	Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides (ACCESSWIRE)
08:30AM	Loading…
Jul-23-25 08:30AM	NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value (ACCESSWIRE)
Jul-21-25 06:30AM	Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides (ACCESSWIRE)
Jul-16-25 08:30AM	WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides (ACCESSWIRE) +9.59%
Jul-14-25 06:30AM	Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides (ACCESSWIRE) +14.70%
Jul-01-25 06:30AM	There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate (ACCESSWIRE)
Jun-18-25 06:30AM	With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
Jun-04-25 06:55AM	NanoViricides Measles Drug Development Animal Study is Imminent (ACCESSWIRE) +6.80%
May-28-25 06:30AM	NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 (ACCESSWIRE)
May-22-25 06:30AM	The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
May-16-25 06:30AM	NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu (ACCESSWIRE) +7.63%
May-15-25 05:16PM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
May-14-25 06:30AM	Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution (ACCESSWIRE)
May-08-25 06:30AM	Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo (ACCESSWIRE) +13.71%
May-05-25 06:30AM	NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC (Newsfile)
Apr-29-25 06:30AM	Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It (ACCESSWIRE)
Mar-11-25 06:30AM	NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company (ACCESS Newswire) +11.21%
Mar-04-25 06:30AM	Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan (ACCESS Newswire)
Feb-19-25 06:30AM	NanoViricides, Inc. Has Filed its Quarterly Report (ACCESS Newswire)
Feb-14-25 04:37PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
11:29AM	Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? (Insider Monkey)
Feb-11-25 06:30AM	NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape (ACCESS Newswire)
Jan-29-25 06:30AM	NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025 (ACCESS Newswire)
Jan-27-25 06:30AM	NanoViricides Engages CRO for Phase II Clinical Trial (ACCESS Newswire)
Jan-13-25 06:30AM	NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 (ACCESSWIRE) -10.37%
Jan-08-25 06:30AM	Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals (ACCESSWIRE) -9.15%
Dec-23-24 06:30AM	NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape (ACCESSWIRE)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire)
Nov-15-24 06:30AM	NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID (ACCESSWIRE) -8.21%
Nov-14-24 07:20PM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Nov-04-24 12:00AM	NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am (ACCESSWIRE)
Oct-22-24 06:30AM	NanoViricides President Dr. Diwan to Present at the PODD Conference (ACCESSWIRE)
Oct-15-24 06:30AM	NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology (ACCESSWIRE)
Oct-14-24 01:30PM	NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy (Insider Monkey)
Oct-08-24 06:30AM	NanoViricides to Present at the Global AMR Summit 2024 Tomorrow (ACCESSWIRE)
Sep-30-24 06:30AM	NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID (ACCESSWIRE)
Sep-26-24 06:30AM	NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including Trojan Horse Drugs (ACCESSWIRE) +5.19%
Aug-26-24 07:30AM	MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX (ACCESSWIRE) +5.26%
Aug-19-24 06:30AM	NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -?A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections (ACCESSWIRE) -5.07%
Aug-08-24 06:30AM	NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
Aug-02-24 07:00AM	Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses? (Newsfile)
Aug-01-24 06:30AM	"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides (ACCESSWIRE)
Jul-24-24 06:30AM	COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides (ACCESSWIRE)
Jul-11-24 06:30AM	A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides (ACCESSWIRE)
Jun-26-24 10:34AM	NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model (News Direct)
Jun-24-24 06:00AM	A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides (ACCESSWIRE) +5.49%
Jun-20-24 06:30AM	A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model (ACCESSWIRE) +23.78%
Jun-11-24 06:30AM	Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect (ACCESSWIRE) +9.24%
Jun-04-24 06:30AM	The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect (ACCESSWIRE)
May-29-24 06:30AM	A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More (ACCESSWIRE) +10.45%
May-23-24 06:30AM	NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc. (ACCESSWIRE)
May-20-24 06:30AM	Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure (ACCESSWIRE)
May-15-24 06:58AM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -20.35%
06:30AM	NanoViricides Has Filed its Quarterly Report (ACCESSWIRE)
May-14-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against RSV (ACCESSWIRE) +24.18%
May-10-24 06:30AM	NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City (ACCESSWIRE)
May-08-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox (ACCESSWIRE) +20.83%
May-06-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against Influenza A (ACCESSWIRE) +23.89%
May-02-24 06:30AM	3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace) +6.19%
Apr-30-24 06:30AM	NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon (ACCESSWIRE) +6.19%
Feb-15-24 06:30AM	NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon (ACCESSWIRE)
Feb-14-24 05:11PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-01-24 06:20AM	Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
Jan-29-24 06:30AM	Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found (ACCESSWIRE) +9.35%
Jan-04-24 06:30AM	NanoViricides to Present at the Biotech Showcase in San Fransisco (ACCESSWIRE) +5.83%
Nov-29-23 01:32PM	NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387 (News Direct)
Nov-28-23 06:40AM	The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Companys Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides (ACCESSWIRE) +13.73%
Nov-15-23 06:45AM	NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications (ACCESSWIRE) -9.70%
05:04AM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Nov-14-23 06:45AM	Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development (ACCESSWIRE) +11.67%

NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. It focuses on anti-viral therapeutics through internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NNVC

NanoViricides Inc

Upgrade your FINVIZ experience